Regulatory

QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed

2023-05-11
PDF
Report
Presentation
Webcast

Ascelia Pharma AB (publ) (ticker: ACE) today published its Q1 financial report for 2023 (January – March 2023), which is now available on the company’s website:

https://www.ascelia.com/ir-media/financial-reports/

SIGNIFICANT EVENTS IN Q1 2023

  • Ascelia Pharma achieves last patient last visit (LPLV) in the Orviglance Phase 3 Sparkle study which now includes 85 completed patients
  • Investor update: Bringing Orviglance to market – Next steps towards launch
  • Third US Patent strengthens patent protection for Ascelia Pharma´s Oncoral (daily tablet irinotecan)
  • Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program
  • Ascelia Pharma mourns the passing of board member René Spogárd

SIGNIFICANT EVENTS AFTER THE PERIOD

  • No significant events after the period

FINANCIAL SUMMARY Q1 2023

  • Operating result of SEK -36.7M (SEK -32.6M)
  • Earnings per share of SEK -1.07 (SEK -0.84)
  • Cash flow from operations of SEK -37.5M (SEK -31.4M)
  • Cash and marketable securities of SEK 111.4M (SEK 232.6M)

Following an intense and challenging 2022, we continued to make steady progress in the first quarter 2023, where the completion of patient enrollment for the phase 3 study with Orviglance, SPARKLE, puts us on course for a successful 2023.”, said Magnus Corfitzen, CEO at Ascelia Pharma.

A presentation for analysts, investors and media will be held today 11 May at 10:00am CET. The event will be hosted by the company’s CEO Magnus Corfitzen, Deputy CEO & CCO Julie Waras Brogren, CFO Déspina Georgiadou Hedin and CSO Andreas Norlin. The presentation will be held in English. The presentation can be followed live via the link: https://ir.financialhearings.com/ascelia-pharma-q1-2023

To participate via teleconference, please register through the link below. After registration, you will be provided phone numbers and a conference ID to access the conference.
https://conference.financialhearings.com/teleconference/?id=200756

It will also be possible to take part of the audiocast afterwards at the same address or at Ascelia Pharma’s website: https://www.ascelia.com/ir-media/financial-reports/